Oltipraz chemoprevention trial in Qidong, People's Republic of China: Study design and clinical outcomes

Cancer Epidemiology Biomarkers and Prevention

Volumn 6, Issue 4, 1997, Pages 257-265

  Jacobson, Lisa P ^d   Zhang, Bao Chu ^a   Zhu, Yuan Ronsssg ^a   Wang, Jin Bing ^a   Wu, Yan ^a   Zhang, Qi Nan ^a   Yu, Lu Yi ^b   Qian, Geng Sun ^c   Kuang, Shuang Yuan ^c   Li, Yan Feng ^c   Fang, Xi ^c   Zarba, Audrey ^d   Chen, Baibai ^d   Enger, Cheryl ^e   Davidson, Nancy E ^e   Gorman, Mary B ^d   Gordon, Gary B ^e   Prochaska, Hans J ^f   Egner, Patricia A ^d   Groopman, John D ^d,e   Muñoz, Alvaro ^d   Helzlsouer, Kathy J ^d,e   Kensler, Thomas W ^d,e   more..

^a QIDONG LIVER CANCER INSTITUTE   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI CANCER INSTITUTE   (China)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; OLTIPRAZ;

ADULT; AGED; ARTICLE; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG HYPERSENSITIVITY; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 16944362010     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Zhu, Y-R., Chen, J-G., and Huang, X. Y. Hepatocellular carcinoma in Qidong County. In: Z. Y. Tang (ed.). Primary Liver Cancer, pp. 204-222. Beijing: Springer Verlag, 1989.
2. Yu, S-Z. Primary prevention of hepatocellular carcinoma. J. Gastroenterol. Hepatol., 10: 674-682, 1995.
3. Ross, R. K., Yuan, J-M., Yu, M. C., Wogan, G. N., Qian, G-S., Tu, J-T., Groopman, J. D., Gao, Y-T., and Henderson, B. E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339: 943-946, 1992.
4. Qian, G-S., Ross, R. K., Yu, M. C., Yuan, J-M., Gao, Y-T., Henderson, B. E., Wogan, G. N., and Groopman, J. D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol., Biomarkers & Prev., 3: 3-10, 1994.
5. Melnick, J. L. Hepatocellular carcinoma caused by hepatitis B virus. In: A. S. Evans (ed.). Viral Infections of Humans. Epidemiology and Control, 3rd Ed., pp. 769-780. New York: Plenum Press, 1989.
6. Ueno, Y., Nagata, S., Tsutsumi, T., Hasegawa, A., Watanabe, M. F., Park, H-D., Chen, G-C., Chen, G., and Yu, S-Z. Detection of microcystins, a blue-green algal hepatotoxin, in drinking water sampled in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay. Carcinogenesis (Lond.), 17: 1317-1321, 1996.
7. Wang, J-S., Qian, G-S., Zarba, A., He, X., Zhu, Y-R., Zhang, B-C., Jacobson, L., Gange, S. J., Muñoz, A., Kensler, T. W., and Groopman, J. D. Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. Cancer Epidemiol., Biomarkers & Prev., 5: 253-261, 1996.
8. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
9. 1 induces the transversion of G to T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA, 90: 8586-8590, 1993.
10. 1-induced hepatocarcinogenesis in rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res., 51: 5501-5506, 1991.
11. Helzlsouer, K. J., and Kensler, T. W. Cancer chemoprevention by Oltipraz: experimental and clinical considerations. Prev. Med., 22: 783-795, 1993.
12. Primiano, T., Egner, P. A., Suiter, T. R., Kelloff, G. J., Roebuck, B. D., and Kensler, T. W. Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res., 55: 4319-4324, 1995.
13. Bolton, M. G., Muñoz, A., Jacobson, L. P., Groopman, J. D., Maxuitenko, Y., Roebuck, B. D., and Kensler, T. W. Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. Cancer Res., 53: 3499-3504, 1993.
14. Egner, P. A., Gange, S. J., Dolan, P. M., Groopman, J. D., Muñoz, A., and Kensler, T. W. Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis (Lond.), 16: 1769-1773, 1995.
15. Dimitrov, N. V., Bennett, J. L., McMillan, J., Perloff, M., Leece, C. M., and Malone, W. Clinical pharmacology studies of oltipraz - a potential chemopreventive agent. Invest. New Drugs, 10: 289-298, 1992.
16. Benson, A. B., III. Oltipraz: a laboratory and clinical review. J. Cell. Biochem., 17F: 278-291, 1993.
17. Gupta, E., Olopade, O. L., Ratain, M. J., Mick, R., Baker, T. M., Berezin, F. K., Benson, A. B., III, and Dolan, M. E. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. J. Clin. Oncol., 1: 1133-1138, 1995.
18. Egner, P. A., Kensler, T. W., Prestera, T., Talalay, P., Libby, A. H., and Curphey, T. J. Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. Carcinogenesis (Lond.), 15: 177-181, 1994.
19. Tangrea, J. A., Adrianza, M. E., and McAdams, M. A method for the detection and management of adverse events in clinical trials. Drug Information J., 25: 63-80, 1991.
20. Miller, R. G. Survival Analysis, pp. 143-146. New York: John Wiley & Sons, Inc., 1981.
21. Meinert, C. L. Clinical Trials: Design, Conduct, and Analysis, p. 161. New York: Oxford University Press, 1986.
22. Szarka, C. E., Grana, G., and Engstrom, P. F. Chemoprevention of cancer. Curr. Probl. Cancer, 18: 6-79, 1994.
23. Gentilini, M., Duflo, B., Richard-Lenoble, D., Brücker, G., Danis, M., Niel, G., and Muenier, Y. Assessment of 35972 RP (Oltipraz), a new antischistosomal drug against Schistosoma haematobium, Schistosoma mansoni, and Schistosoma intercalatum. Acta Trop., 37: 271-274, 1980.
24. Bella, H., Rahim, A. G. A., Mustafa, M. D., Ahmed, M. A. M., Wasfi, S., and Bennett, J. L. Oltipraz - antischistosomal efficacy in Sudanese infected with Schistosoma mansoni. Am. J. Trop. Med. Hyg., 31: 775-778, 1982.
25. Katz, N., Rocha, R. S., and Chaves, A. Dose-ranging clinical trial with Oltipraz in Schistosomiasis mansoni. Rev. Inst. Med. Trop. São Paulo, 24: 40-48, 1982.
26. Igail, A. B. E., Tayeb, M. E., Karadaman, M. W., Daffalla, A. A., Dixon, H. G., and Fenwick, A. Dose-finding trial using Oltipraz to treat schoolchildren infected with Schistosoma mansoni in Gezira, Sudan. J. Trop. Med. Hyg., 88: 101-104, 1985.